康复新液联合杀灭幽门螺杆菌治疗慢性萎缩性胃炎的临床疗效观察

Clinical observation on the effect of Kangfuxin liquid combined with killing Helicobacter pylori on chronic atrophic gastritis

目的:观察康复新液与胶体果胶铋、兰索拉唑、甲硝唑及阿莫西林联合杀灭幽门螺杆菌治疗慢性萎缩性胃炎的临床疗效及安全性。方法:收治幽门螺杆菌阳性伴有慢性萎缩性胃炎患者76例,随机平分两组。对照组给予兰索拉唑、甲硝唑及阿莫西林等四联疗法杀灭幽门螺杆菌治疗。试验组除上述治疗外,加用康复新液治疗。比较两组患者的治疗前后临床疗效、幽门螺杆菌杀灭率、胃镜及病理切片检查结果。结果:试验组有效率、临床症状缓解状况及胃镜、病理学检查结果评估均明显高于对照组。两组疗效比较差异有统计学意义(P<0.05)。两组幽门螺杆菌杀灭率比较差异有统计学意义(P<0.05)。在治疗过程中均未发生明显不良反应。结论:康复新液联合胶体果胶铋、兰索拉唑、甲硝唑及阿莫西林杀灭幽门螺杆菌治疗慢性萎缩性胃炎的临床疗效显著,且安全可靠。

Objective:To observe the efficacy and safety of Kangfuxin liquid combined with colloidal bismuth pectin,lansoprazole, metronidazole and amoxicillin in the treatment of chronic atrophic gastritis.Methods:76 cases of Helicobacter pylori positive patients with chronic atrophic gastritis were selected,they were randomly divided into the two groups.The control group was given lansoprazole,metronidazole and amoxicillin quadruple therapy to kill Helicobacter pylori.In addition to the above treatment,the experimental group was treated with Kangfuxin solution.The clinical efficacy,Helicobacter pylori eradication rate,gastroscopy and pathological examination results of the two groups were compared before and after treatment.Results:The effective rate,clinical symptoms relief,gastroscopy and pathological examination results of the experimental group were significantly higher than those of the control group.There was significant difference between the two groups(P<0.05).The killing rate of Helicobacter pylori was significantly different between the two groups(P<0.05).No obvious adverse reactions occurred during the treatment.Conclusion: Kangfuxin liquid combined with colloidal bismuth pectin,lansoprazole,metronidazole and amoxicillin is effective and safe in the treatment of chronic atrophic gastritis.